Real-world data of HER2-low metastatic breast cancer: A population based cohort study

In this study, researchers of the PHARMO Institute compared clinicopathologic characteristics and survival of patients with metastatic breast cancer according to the level of HER2 expression, using data from the PALGA Foundation and PHARMO Data Network.

In this article the researchers showed that a substantial proportion of selected women with distant metastatic breast cancer had a HER2-low breast cancer. HER2 expression levels differed between the primary tumour and the metastases, thereby making it important to assess HER2 status in both the primary tumour and metastases. Finally, the researchers concluded that no clear differences in survival were found when comparing HER2 and hormone receptor status.

Please click this link when you want to read more about this study.